The DOI matches its Crossref record; 196 of the 196 references it cites were found in a registry or an index.
Personalized Management of Pheochromocytoma and Paraganglioma
Open accessAbstract
Pheochromocytomas/paragangliomas are characterized by a unique molecular landscape that allows their assignment to clusters based on underlying genetic alterations. With around 30% to 35% of Caucasian patients (a lower percentage in the Chinese population) showing germline mutations in susceptibility genes, pheochromocytomas/paragangliomas have the highest rate of heritability among all tumors. A further 35% to 40% of Caucasian patients (a higher percentage in the Chinese population) are affected by somatic driver mutations. Thus, around 70% of all patients with pheochromocytoma/paraganglioma can be assigned to 1 of 3 main molecular clusters with different phenotypes and clinical behavior. Krebs cycle/VHL/EPAS1-related cluster 1 tumors tend to a noradrenergic biochemical phenotype and require very close follow-up due to the risk of metastasis and recurrence. In contrast, kinase signaling–related cluster 2 tumors are characterized by an adrenergic phenotype and episodic symptoms, with generally a less aggressive course. The clinical correlates of patients with Wnt signaling–related cluster 3 tumors are currently poorly described, but aggressive behavior seems likely. In this review, we explore and explain why cluster-specific (personalized) management of pheochromocytoma/paraganglioma is essential to ascertain clinical behavior and prognosis, guide individual diagnostic procedures (biochemical interpretation, choice of the most sensitive imaging modalities), and provide personalized management and follow-up. Although cluster-specific therapy of inoperable/metastatic disease has not yet entered routine clinical practice, we suggest that informed personalized genetic-driven treatment should be implemented as a logical next step. This review amalgamates published guidelines and expert views within each cluster for a coherent individualized patient management plan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 1×
“This causes HIF-α stabilization, mitochondrial DNA impairment, collagen instability, and most likely an abnormal immune microenvironment (45-48).”
BackgroundLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693 · cited 1×
“Through HIF-α stabilization, cluster 1 mutations promote angiogenesis (eg, vascular endothelial growth factor (VEGF)/PDGF transcription), tumor extravasation, migration, invasion, metastasis, and other cellular processes (49-51).”
BackgroundYao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,292
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Self-citationComprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Fishbein, L., Leshchiner, I., Walter, V., Danilova, L., Robertson, A. G., Johnson, A. R., Lichtenberg, T. M., Murray, B. A., Ghayee, H. K., Else, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.001 · Cited by 789
Self-citationSDH mutations establish a hypermethylator phenotype in paraganglioma
Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776 · cited 2×
“Overall, the highest metastatic risk is reported for SDHB (35%-75%), SDHA (30%-66%), and HIF2A/EPAS1 mutation carriers (>30%) (37, 40, 49, 63, 72-79).”
BackgroundThompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
Preoperative Management of the Pheochromocytoma Patient
Pacak, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1720 · Cited by 576
Self-citationvan Nederveen, F. H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R. A., de Bruyn, E. M., Sleddens, H. F., Derkx, P., Rivière, J., Dannenberg, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70164-0 · Cited by 538
Self-citationParaganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez-Roqueplo, A.-P. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 490
Plouin, P. F., Amar, L., Dekkers, O. M., Fassnacht, M., Gimenez-Roqueplo, A. P., Lenders, J. W. M., Lussey-Lepoutre, C., Steichen, O., & _, _. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0033 · Cited by 480
Self-citationClinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours
Lam, A. K.-Y. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9484-5 · Cited by 462
Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 436
Self-citationAverbuch, S. D., Steakley, C. S., Young, R. C., Gelmann, E. P., Goldstein, D. S., Stull, R., & Keiser, H. R. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-267 · Cited by 427
Posterior retroperitoneoscopic adrenalectomy–results of 560 procedures in 520 patients
Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., Ommer, A., Groeben, H., Peitgen, K., Janssen, O. E., et al. (2006) · Surgery · doi:10.1016/j.surg.2006.07.039 · Cited by 425
Lenders, J. W. M., Kerstens, M. N., Amar, L., Prejbisz, A., Robledo, M., Taieb, D., Pacak, K., Crona, J., Zelinka, T., Mannelli, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002438 · Cited by 413
Self-citationTaïeb, D., Hicks, R. J., Hindié, E., Guillet, B. A., Avram, A., Ghedini, P., Timmers, H. J., Scott, A. T., Elojeimy, S., Rubello, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04398-1 · Cited by 403
Self-citationSomatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia
Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E., Popovic, V., Stratakis, C. A., Prchal, J. T., & Pacak, K. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205119 · Cited by 397
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
Castro-Vega, L. J., Buffet, A., De Cubas, A. A., Cascón, A., Menara, M., Khalifa, E., Amar, L., Azriel, S., Bourdeau, I., Chabre, O., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt639 · Cited by 397
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0494 · Cited by 393
Amar, L., Servais, A., Gimenez-Roqueplo, A.-P., Zinzindohoue, F., Chatellier, G., & Plouin, P.-F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1398 · Cited by 390
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
Qin, Y., Yao, L., King, E. E., Buddavarapu, K., Lenci, R. E., Chocron, E. S., Lechleiter, J. D., Sass, M., Aronin, N., Schiavi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.533 · Cited by 379
Eisenhofer, G., Lenders, J. W. M., Linehan, W. M., Walther, M. M., Goldstein, D. S., & Keiser, H. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402404 · Cited by 349
Self-citationEisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.016 · Cited by 334
Self-citationSchlisio, S., Kenchappa, R. S., Vredeveld, L. C. W., George, R. E., Stewart, R., Greulich, H., Shahriari, K., Nguyen, N. V., Pigny, P., Dahia, P. L., et al. (2008) · Genes & Development · doi:10.1101/gad.1648608 · Cited by 333
MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
Burnichon, N., Cascón, A., Schiavi, F., Morales, N. P., Comino-Méndez, I., Abermil, N., Inglada-Pérez, L., de Cubas, A. A., Amar, L., Barontini, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0160 · Cited by 331
Self-citationNew Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Self-citationPryma, D. A., Chin, B. B., Noto, R. B., Dillon, J. S., Perkins, S. M., Sólnes, L. B., Kostakoğlu, L., Serafini, A. N., Pampaloni, M. H., Jensen, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217463 · Cited by 320
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
Hamidi, O., Young, W. F., Iñiguez-Ariza, N. M., Kittah, N. E., Gruber, L., Bancos, C., Tamhane, S., & Bancos, I. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00992 · Cited by 316
Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma
Burnichon, N., Vescovo, L., Amar, L., Libé, R., de Reynies, A., Venisse, A., Jouanno, E., Laurendeau, I., Parfait, B., Bertherat, J., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr324 · Cited by 309
Current Management of Pheochromocytoma
REMINE, W. H., CHONC, G. C., VAN HEERDEN, J. A., SHEPS, S. G., & HARRISON, E. G. (1974) · Annals of Surgery · doi:10.1097/00000658-197405000-00029 · Cited by 299
Mitochondrial complex ii: At the crossroads
Bezawork-Geleta, A., Rohlena, J., Dong, L., Pacak, K., & Neuzil, J. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.01.003 · Cited by 295 · cited 1×
“Cluster 1A mutations (SDHA[AF2]/B/C/D, FH, MDH2, IDH, GOT2, SLC25A11 and DLST) disrupt the Krebs cycle and result in severe impairment of mitochondrial oxidative phosphorylation (43).”
BackgroundEisenhofer, G., Lenders, J. W., Timmers, H., Mannelli, M., Grebe, S. K., Hofbauer, L. C., Bornstein, S. R., Tiebel, O., Adams, K., Bratslavsky, G., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.153320 · Cited by 290
Self-citationAn Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes
Gimenez-Roqueplo, A.-P., Dahia, P., & Robledo, M. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1301302 · Cited by 288
Rednam, S. P., Erez, A., Druker, H., Janeway, K. A., Kamihara, J., Kohlmann, W. K., Nathanson, K. L., States, L. J., Tomlinson, G. E., Villani, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0547 · Cited by 280
Loh, K.-C., Fitzgerald, P. A., Matthay, K. K., Yeo, P. P. B., & Price, D. C. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03348026 · Cited by 278
Timmers, H. J. L. M., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2315 · Cited by 276
Self-citationJanssen, I., Blanchet, E. M., Adams, K., Chen, C. C., Millo, C. M., Herscovitch, P., Taieb, D., Kebebew, E., Lehnert, H., Fojo, A. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2751 · Cited by 276
Self-citationHuang, H., Abraham, J., Hung, E., Averbuch, S. D., Merino, M. J., Steinberg, S. M., Pacák, K., & Fojo, T. (2008) · Cancer · doi:10.1002/cncr.23812 · Cited by 267
Eisenhofer, G., Walther, M. M., Huynh, T.-T., Li, S.-T., Bornstein, S. R., Vortmeyer, A., Mannelli, M., Goldstein, D. S., Linehan, W. M., Lenders, J. W. M., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7496 · Cited by 267
Self-citationBlake, M. A., Cronin, C. G., & Boland, G. W. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.10.4547 · Cited by 253
Andrews, K. A., Ascher, D. B., Pires, D. E. V., Barnes, D. R., Vialard, L., Casey, R. T., Bradshaw, N., Adlard, J., Aylwin, S., Brennan, P., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105127 · Cited by 248
Gonias, S., Goldsby, R., Matthay, K. K., Hawkins, R., Price, D., Huberty, J., Damon, L., Linker, C., Sznewajs, A., Shiboski, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3496 · Cited by 245
Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function
Bailis, W., Shyer, J. A., Zhao, J., Canaveras, J. C. G., Al Khazal, F. J., Qu, R., Steach, H. R., Bielecki, P., Khan, O., Jackson, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1311-3 · Cited by 240
Pheochromocytoma in Italy: a multicentric retrospective study
Mannelli, M., Ianni, L., Cilotti, A., & Conti, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410619 · Cited by 228
Van Essen, M., Krenning, E. P., De Jong, M., Valkema, R., & Kwekkeboom, D. J. (2007) · Acta Oncologica · doi:10.1080/02841860701441848 · Cited by 221
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215
Ayala-Ramirez, M., Chougnet, C. N., Habra, M. A., Palmer, J. L., Leboulleux, S., Cabanillas, M. E., Caramella, C., Anderson, P., Al Ghuzlan, A., Waguespack, S. G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2356 · Cited by 212
Hadoux, J., Favier, J., Scoazec, J., Leboulleux, S., Al Ghuzlan, A., Caramella, C., Déandreis, D., Borget, I., Loriot, C., Chougnet, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28913 · Cited by 210
Eisenhofer, G., Lenders, J. W., Goldstein, D. S., Mannelli, M., Csako, G., Walther, M. M., Brouwers, F. M., & Pacak, K. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.045484 · Cited by 208
Self-citationEisenhofer, G., Huynh, T.-T., Pacak, K., Brouwers, F. M., Walther, M. M., Linehan, W. M., Munson, P. J., Mannelli, M., Goldstein, D. S., & Elkahloun, A. G. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00838 · Cited by 207
Self-citationSpectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas
Yao, L., Schiavi, F., Cascon, A., Qin, Y., Inglada-Pérez, L., King, E. E., Toledo, R. A., Ercolino, T., Rapizzi, E., Ricketts, C. J., et al. (2010) · JAMA · doi:10.1001/jama.2010.1830 · Cited by 202
Self-citationTurnover and Metabolism of Catecholamines in Patients with Pheochromocytoma*
Crout, J. R., & Sjoerdsma, A. (1964) · Journal of Clinical Investigation · doi:10.1172/jci104898 · Cited by 200
Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma
Eisenhofer, G., Pacak, K., Huynh, T.-T., Qin, N., Bratslavsky, G., Linehan, W. M., Mannelli, M., Friberg, P., Grebe, S. K., Timmers, H. J., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0211 · Cited by 189
Self-citationAn overview of 20 years of genetic studies in pheochromocytoma and paraganglioma
Buffet, A., Burnichon, N., Favier, J., & Gimenez-Roqueplo, A.-P. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101416 · Cited by 189
Hescot, S., Curras-Freixes, M., Deutschbein, T., van Berkel, A., Vezzosi, D., Amar, L., de la Fouchardière, C., Valdes, N., Riccardi, F., Do Cao, C., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01968 · Cited by 188
Self-citationJanssen, I., Chen, C. C., Taieb, D., Patronas, N. J., Millo, C. M., Adams, K. T., Nambuba, J., Herscovitch, P., Sadowski, S. M., Fojo, A. T., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161018 · Cited by 187
Self-citationVon Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome
Nielsen, S. M., Rhodes, L., Blanco, I., Chung, W. K., Eng, C., Maher, E. R., Richard, S., & Giles, R. H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6140 · Cited by 186
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Fishbein, L., Khare, S., Wubbenhorst, B., DeSloover, D., D’Andrea, K., Merrill, S., Cho, N. W., Greenberg, R. A., Else, T., Montone, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms7140 · Cited by 185
Eisenhofer, G., Prejbisz, A., Peitzsch, M., Pamporaki, C., Masjkur, J., Rogowski-Lehmann, N., Langton, K., Tsourdi, E., Pęczkowska, M., Fliedner, S., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.291369 · Cited by 181
Self-citationCastinetti, F., Qi, X.-P., Walz, M. K., Maia, A. L., Sansó, G., Peczkowska, M., Hasse-Lazar, K., Links, T. P., Dvorakova, S., Toledo, R. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70154-8 · Cited by 181
Metyrosine and Pheochromocytoma
Steinsapir, J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.8.901 · Cited by 176
Strong, V. E., Kennedy, T., Al-Ahmadie, H., Tang, L., Coleman, J., Fong, Y., Brennan, M., & Ghossein, R. A. (2008) · Surgery · doi:10.1016/j.surg.2008.02.007 · Cited by 174
Welander, J., Andreasson, A., Juhlin, C. C., Wiseman, R. W., Bäckdahl, M., Höög, A., Larsson, C., Gimm, O., & Söderkvist, P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4375 · Cited by 173
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
Self-citationNölting, S., Ullrich, M., Pietzsch, J., Ziegler, C. G., Eisenhofer, G., Grossman, A., & Pacak, K. (2019) · Cancers · doi:10.3390/cancers11101505 · Cited by 172
Self-citationCurrent Approaches and Recent Developments in the Management of Head and Neck Paragangliomas
Taïeb, D., Kaliski, A., Boedeker, C. C., Martucci, V., Fojo, T., Adler, J. R., & Pacak, K. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1026 · Cited by 170
Self-citationInternational consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers
Amar, L., Pacak, K., Steichen, O., Akker, S. A., Aylwin, S. J. B., Baudin, E., Buffet, A., Burnichon, N., Clifton-Bligh, R. J., Dahia, P. L. M., et al. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00492-3 · Cited by 170
Self-citationAngiogenesis and Vascular Architecture in Pheochromocytomas
Favier, J., Plouin, P., Corvol, P. L., & Gasc, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64400-8 · Cited by 164
Ayala‐Ramirez, M., Feng, L., Habra, M. A., Rich, T., Dickson, P. V., Perrier, N., Phan, A., Waguespack, S., Patel, S., & Jimenez, C. (2012) · Cancer · doi:10.1002/cncr.26577 · Cited by 161
van Essen, M., Krenning, E. P., Kooij, P. P. M., Bakker, W. H., Feelders, R. A., de Herder, W. W., Wolbers, J. G., & Kwekkeboom, D. J. (2006) · PubMed · Cited by 161
Review of Pediatric Pheochromocytoma and Paraganglioma
Bholah, R., & Bunchman, T. E. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00155 · Cited by 160
Long-term prognosis of patients with pediatric pheochromocytoma
Bausch, B., Wellner, U., Bausch, D., Schiavi, F., Barontini, M., Sanso, G., Walz, M. K., Peczkowska, M., Weryha, G., Dall'Igna, P., et al. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0415 · Cited by 159
Self-citationBuffet, A., Morin, A., Castro‐Vega, L. J., Habarou, F., Lussey‐Lepoutre, C., Letouzé, É., Lefèbvre, H., Guilhem, I., Haissaguerre, M., Raingeard, I., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2463 · Cited by 159
Adverse Drug Reactions in Patients with Phaeochromocytoma: Incidence, Prevention and Management
Eisenhofer, G., Rivers, G., Rosas, A. L., Quezado, Z., Manger, W. M., & Pacák, K. (2007) · Drug Safety · doi:10.2165/00002018-200730110-00004 · Cited by 158
Self-citationBuitenwerf, E., Osinga, T. E., Timmers, H. J. L. M., Lenders, J. W. M., Feelders, R. A., Eekhoff, E. M. W., Haak, H. R., Corssmit, E. P. M., Bisschop, P. H. L. T., Valk, G. D., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz188 · Cited by 158
Neumann, H. P. H., Tsoy, U. A., Bancos, I., Amodru, V., Walz, M. K., Tirosh, A., Kaur, R. J., McKenzie, T. J., Qi, X.-P., Bandgar, T., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8898 · Cited by 155
Toledo, R. A., Qin, Y., Cheng, Z.-M., Gao, Q., Iwata, S., Silva, G. M., Prasad, M. L., Ocal, I. T., Rao, S. N., D, N. A. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1841 · Cited by 153
New syndrome of paraganglioma and somatostatinoma associated with polycythemia.
Pacak, K., Jochmanová, I., Prodanov, T., Yang, C.-Z., Merino, M., Fojo, T., Prchal, J., Tischler, A., Lechan, R., & Zhuang, Z. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1912 · Cited by 148
Self-citationJob, S., Drašković, I., Burnichon, N., Buffet, A., Cros, J. F., Lépine, C., Vénisse, A., Robidel, E., Verkarre, V., Méatchi, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0139 · Cited by 148
Turková, H., Prodanov, T., Malý, M., Martucci, V. L., Adams, K. T., Widimsky, J., Jr., Chen, C. C., Ling, A. L., Kebebew, E., Stratakis, C. A., et al. (2015) · Endocrine Practice · doi:10.4158/ep15725.or · Cited by 147
Icard, P., & Lincet, H. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.001 · Cited by 146
Geroula, A., Deutschbein, T., Langton, K., Masjkur, J. R., Pamporaki, C., Peitzsch, M., Fliedner, S. M. J., Timmers, H. J. L. M., Bornstein, S. R., Beuschlein, F., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0159 · Cited by 146
Self-citationCrona, J., Lamarca, Á., Ghosal, S., Welin, S., Skogseid, B. M., & Pacák, K. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0024 · Cited by 140
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Naing, A., Meric‐Bernstam, F., Stephen, B., Karp, D. D., Hajjar, J., Rodon, J. A., Piha-Paul, S. A., Colen, R. R., Jiménez, C., Raghav, K. P. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000347 · Cited by 139
Fonte, J. S., Robles, J., Chen, C. C., Reynolds, J. C., Whatley, M. A., Ling, A. L., MERCADO-ASIS, L. B., Adams, K. T., Martucci, V. L., Fojo, T., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0243 · Cited by 137
Taïeb, D., Jha, A., Treglia, G., & Pacák, K. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0165 · Cited by 137
O'Kane, G. M., Ezzat, S., Joshua, A. M., Bourdeau, I., Leibowitz‐Amit, R., Olney, H. J., Krzyzanowska, M. K., Reuther, D., Chin, S. F., Wang, L. E., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0474-x · Cited by 136
Ayala‐Ramirez, M., Palmer, J. L., Hofmann, M.-C. C., de la Cruz, M., Moon, B. S., Waguespack, S. G., Habra, M. A., & Jiménez, C. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4231 · Cited by 134
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
Forrer, F., Riedweg, I., Maëcke, H. R., & Mueller‐Brand, J. (2008) · PubMed · Cited by 134
Archier, A., Varoquaux, A. D., Garrigue, P., Montava, M., Guérin, C., Gabriel, S., Beschmout, E., Morange, I., Fakhry, N., Castinetti, F., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3268-2 · Cited by 132
Chromogranin A Storage and Secretion
Hsiao, R. J., Parmer, R. J., TAKIYYUDDIN, M. A., & O’Connor, D. T. (1991) · Medicine · doi:10.1097/00005792-199101000-00003 · Cited by 125
Hamidi, O., Young, W. F., Gruber, L., Smestad, J. A., Yan, Q., Ponce, O. J., Prokop, L. J., Murad, M. H., & Bancos, I. (2017) · Clinical Endocrinology · doi:10.1111/cen.13434 · Cited by 124
Därr, R., Pamporaki, C., Peitzsch, M., Miehle, K., Prejbisz, A., Pęczkowska, M., Weismann, D., Beuschlein, F., Sinnott, R., Bornstein, S. R., et al. (2013) · Clinical Endocrinology · doi:10.1111/cen.12327 · Cited by 122
Self-citationSatapathy, S., Mittal, B. R., & Bhansali, A. K. (2019) · Clinical Endocrinology · doi:10.1111/cen.14106 · Cited by 121
Timmers, H. J. L. M., Pacak, K., Huynh, T. T., Abu-Asab, M., Tsokos, M., Merino, M. J., Baysal, B. E., Adams, K. T., & Eisenhofer, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1093 · Cited by 114
Self-citationRecurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas
Remacha, L., Pirman, D. A., Mahoney, C. E., Coloma, J., Calsina, B., Currás-Freixes, M., Letón, R., Torres‐Pérez, R., Richter, S., Pita, G., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.017 · Cited by 113
Self-citationTET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition
Morin, A., Goncalves, J., Moog, S., Castro‐Vega, L. J., Job, S., Buffet, A., Fontenille, M., Woszczyk, J., Gimenez‐Roqueplo, A., Letouzé, É., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.022 · Cited by 113
Seabrook, A., Harris, J. E., Velosa, S. B., Kim, E., McInerney-Leo, A. M., Dwight, T., Hockings, J. I., Hockings, N. G., Kirk, J., Leo, P. J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa957 · Cited by 113
Surgical Management of Pheochromocytoma with the Use of Metyrosine
Perry, R. R., Keiser, H. R., Norton, J. A., Wall, R. T., Robertson, C. N., Travis, W. D., Pass, H. I., Walther, M. M., & Linehan, W. M. (1990) · Annals of Surgery · doi:10.1097/00000658-199011000-00010 · Cited by 111
Genomic Landscape of Pheochromocytoma and Paraganglioma
Jochmanová, I., & Pacák, K. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.11.001 · Cited by 111
Eisenhofer, G., Klink, B., Richter, S., Lenders, J. W. M., & Robledo, M. (2017) · Europe PMC (PubMed Central) · Cited by 109
Self-citationGain-of-function mutations in DNMT3A in patients with paraganglioma
Remacha, L., Currás-Freixes, M., Torres-Ruiz, R., Schiavi, F., Torres‐Pérez, R., Calsina, B., Letón, R., Comino‐Méndez, I., Roldán‐Romero, J. M., Montero‐Conde, C., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0003-y · Cited by 108
Navalkissoor, S., & Grossman, A. B. (2018) · Neuroendocrinology · doi:10.1159/000494760 · Cited by 108
Self-citationRemacha, L., Comino‐Méndez, I., Richter, S., Contreras, L., Currás-Freixes, M., Pita, G., Letón, R., Galarreta, A., Torres‐Pérez, R., Honrado, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2250 · Cited by 105
Self-citationSDHB-related pheochromocytoma and paraganglioma penetrance and genotype–phenotype correlations
Jochmanová, I., Wolf, K. I., King, K. S., Nambuba, J., WESLEY, R. A., Martucci, V. L., Raygada, M. J., Adams, K. T., Prodanov, T., Fojo, A. T., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2397-3 · Cited by 104
Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine
Kimura, N., Takekoshi, K., & Naruse, M. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090242 · Cited by 101
Luchetti, A., Walsh, D. M., Rodger, F., Clark, G. R., Martin, T., Irving, R. M., Sanna, M., Yao, M., Robledo, M., Neumann, H. P. H., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/138573 · Cited by 100
Stenman, A., Zedenius, J., & Juhlin, C. C. (2019) · Cancers · doi:10.3390/cancers11020225 · Cited by 98
Jha, A., Ling, A. L., Millo, C., Gupta, G., Viana, B., Lin, F. I., Herscovitch, P., Adams, K. T., Taïeb, D., Metwalli, A. R., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3896-9 · Cited by 97
Patel, D., Phay, J. E., Yen, T. W. F., Dickson, P. V., Wang, T. S., Garcia, R., Yang, A. D., Solórzano, C. C., & Kim, L. T. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08220-3 · Cited by 96
Oh, D., Kim, T., Park, Y. S., Shin, S. J., Shin, S. H., Song, E., Lee, H. J., Lee, K., & Bang, Y. (2012) · Cancer · doi:10.1002/cncr.27675 · Cited by 95
Srirangalingam, U., Walker, L., Khoo, B. C. E., MacDonald, F., Gardner, D. S.-L., Wilkin, T. J., Skelly, R. H., George, E., Spooner, D. A., Monson, J. P., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03274.x · Cited by 93
Self-citationQin, N., de Cubas, A. A., García-Martín, R., Richter, S., Peitzsch, M., Menschikowski, M., Lenders, J. W. M., Timmers, H. J. L. M., Mannelli, M., Opocher, G., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28868 · Cited by 91
Self-citationPacák, K., Ilias, Ι., Adams, K. T., & EISENHOFER, G. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01425.x · Cited by 90
Self-citationJiang, J., Zhang, J., Pang, Y., Bechmann, N., Li, M., Monteagudo, M., Calsina, B., Gimenez‐Roqueplo, A., Nölting, S., Beuschlein, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa502 · Cited by 89
Self-citationCrooks, D. R., Maio, N., Lang, M., Ricketts, C. J., Vocke, C. D., Gurram, S., Turan, S., Kim, Y., Cawthon, G. M., Sohelian, F., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abc4436 · Cited by 87
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE
Vyakaranam, A. R., Crona, J., Norlén, O., Granberg, D. O., Garske‐Román, U., Sandström, M., Fröss‐Baron, K., Thiis‐Evensen, E., Hellman, P., & Sundin, A. (2019) · Cancers · doi:10.3390/cancers11070909 · Cited by 86
Schovánek, J., Martucci, V. L., WESLEY, R. A., Fojo, T., Rivero, J. D., Huynh, T., Adams, K. T., Kebebew, E., Fryšák, Z., Stratakis, C. A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-523 · Cited by 83
Assadipour, Y., Sadowski, S. M., Alimchandani, M., Quezado, M., Steinberg, S. M., Nilubol, N., Patel, D., Prodanov, T., Pacák, K., & Kebebew, E. (2016) · Surgery · doi:10.1016/j.surg.2016.05.050 · Cited by 83
Tanabe, A., Naruse, M., Nomura, K., Tsuiki, M., Tsumagari, A., & Ichihara, A. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0133-2 · Cited by 82
Eisenhofer, G., Huynh, T., Elkahloun, A., Morris, J., Bratslavsky, G., Linehan, W., Zhuang, Z.-P., Balgley, B. M., Lee, C. S., Mannelli, M., et al. (2008) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.90591.2008 · Cited by 81
Self-citationPang, Y. K., Lu, Y., Caisová, V., Liu, Y., Bullova, P., Huynh, T., Zhou, Y., Yu, D., Fryšák, Z., Hartmann, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3406 · Cited by 81
Genotype–phenotype correlations in VHL exon deletions
McNeill, A., Rattenberry, E., Barber, R. M., Killick, P., MacDonald, F., & Maher, E. R. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33023 · Cited by 79
The management of head-and-neck paragangliomas
Capatina, C. A.-M., Ntali, G., Karavitaki, N., & Grossman, A. B. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0223 · Cited by 79
Self-citationInterest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1
Képénékian, L., Mognetti, T., Lifante, J., Giraudet, A., Houzard, C., Pinson, S., Borson‐Chazot, F., & Combemale, P. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0233 · Cited by 79
Jafri, M., Whitworth, J., Rattenberry, E., Vialard, L., Kilby, G., Kumar, A., Izatt, L., Lalloo, F. I., Brennan, P., Cook, J. A., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12074 · Cited by 76
Treatment of Head and Neck Paragangliomas With External Beam Radiation Therapy
Dupin, C. L., Lang, P., Dessard-Diana, B., Simon, J.-M., Cuenca, X., Mazeron, J., & Feuvret, L. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.02.010 · Cited by 75
Recent advances in the diagnosis and treatment of pheochromocytoma in children
Ludwig, A. D., Feig, D. I., Brandt, M. L., Hicks, J. M., Fitch, M. E., & Cass, D. L. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.08.028 · Cited by 74
Jiménez, C., Subbiah, V., Stephen, B., Ma, J., Milton, D. R., Xu, M., Zarifa, A., Akhmedzhanov, F., Tsimberidou, A. M., Habra, M. A., et al. (2020) · Cancers · doi:10.3390/cancers12082307 · Cited by 73
The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers
Rijken, J. A., Niemeijer, N. D., Jonker, M. A., Eijkelenkamp, K., Jansen, J. C., van Berkel, A., Timmers, H. J. L. M., Kunst, H. P. M., Bisschop, P. H. L. T., Kerstens, M. N., et al. (2017) · Clinical Genetics · doi:10.1111/cge.13055 · Cited by 72
Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study
Buitenwerf, E., Korteweg, T., Visser, A., Haag, C. M. S. C., Feelders, R. A., Timmers, H. J. L. M., Canu, L., Haak, H. R., Bisschop, P. H. L. T., Eekhoff, E. M. W., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0006 · Cited by 72
Berends, A. M. A., Kerstens, M. N., Lenders, J. W. M., & Timmers, H. J. L. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa441 · Cited by 72
Bayesian approach to determining penetrance of pathogenic SDH variants
Benn, D. E., Zhu, Y., Andrews, K. A., Wilding, M., Duncan, E. L., Dwight, T., Tothill, R. W., Burgess, J. R., Crook, A., Gill, A. J., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105427 · Cited by 71
Pheochromocytoma: The First Metabolic Endocrine Cancer
Jochmanová, I., & Pacák, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0606 · Cited by 69
Signaling Pathways in Pheochromocytomas and Paragangliomas: Prospects for Future Therapies
Nölting, S., & Grossman, A. B. (2012) · Endocrine Pathology · doi:10.1007/s12022-012-9199-6 · Cited by 68
Self-citationThe Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas
Ellis, R. J., Patel, D., Prodanov, T., Nilubol, N., Pacák, K., & Kebebew, E. (2013) · Annals of Surgery · doi:10.1097/sla.0000000000000283 · Cited by 67
External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma
Vogel, J., Sia-Atanacio, A., Prodanov, T., Turkbey, B. I., Adams, K. T., Martucci, V. L., Camphausen, K. A., Fojo, A. T., Pacák, K., & Kaushal, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00166 · Cited by 67
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome
Därr, R., Nambuba, J., del Rivero, J., Janssen, I., Merino, M., Todorović, M., Balint, B., Jochmanová, I., Prchal, J., Lechan, R. M., et al. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-16-0231 · Cited by 67
Self-citationMetastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options
Nölting, S., Grossman, A. B., & Pacák, K. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1888 · Cited by 65
Self-citationWeismann, D., Peitzsch, M., Raida, A., Prejbisz, A., Gosk-Przybyłek, M., Riester, A., Willenberg, H. S., Klemm, R., Manz, G., Deutschbein, T., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0730 · Cited by 64
Self-citationJha, A., de Luna, K. S., Balili, C. A., Millo, C., Paraiso, C. A., Ling, A. L., Gonzales, M. K., Viana, B., Alrezk, R., Adams, K. T., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00053 · Cited by 64
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas
Bechmann, N., Moskopp, M. L., Ullrich, M., Calsina, B., Wallace, P. W., Richter, S., Friedemann, M., Langton, K., Fliedner, S. M. J., Timmers, H. J. L. M., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0205 · Cited by 64
Self-citationChromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma
Bílek, R., Vlček, P., Šafařík, L., Michalský, D., Novák, K., Duskova, J., Václavíková, E., Widimsky, J., Jr., & Zelinka, T. (2019) · Cancers · doi:10.3390/cancers11040586 · Cited by 62
Derivation of urinary dopamine from plasma dopa
Zimlichman, R., Levinson, P. D., Kelly, G. D., Stull, R., Keiser, H. R., & Goldstein, D. S. (1988) · Clinical Science · doi:10.1042/cs0750515 · Cited by 61
Eisenhofer, G., Deutschbein, T., Constantinescu, G. A., Langton, K., Pamporaki, C., Calsina, B., Monteagudo, M., Peitzsch, M., Fliedner, S. M. J., Timmers, H. J. L. M., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0904 · Cited by 59
Self-citationSurgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series
Strajina, V., Dy, B. M., Farley, D. R., Richards, M. L., McKenzie, T. J., Bible, K. C., Que, F. G., Nagorney, D. M., Young, W. F., & Thompson, G. B. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5739-5 · Cited by 58
Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin.
van der Zee, P. A., & de Boer, A. (2014) · PubMed · Cited by 56
Dahia, P. L. M., Clifton-Bligh, R. J., Gimenez‐Roqueplo, A., Robledo, M., & Jiménez, C. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0435 · Cited by 56
The Clinical Phenotype of SDHC-Associated Hereditary Paraganglioma Syndrome (PGL3)
Else, T., Marvin, M. L., Everett, J. N., Gruber, S. B., Arts, H. A., Stoffel, E. M., Auchus, R. J., & Raymond, V. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3853 · Cited by 55
Jochmanová, I., Abcede, A. M. T., Guerrero, R. J. S., Malong, C. L., WESLEY, R. A., Huynh, T., Gonzales, M. K., Wolf, K. I., Jha, A., Knue, M., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03138-5 · Cited by 55
Role of DOTATATE ‐ PET / CT in preoperative assessment of phaeochromocytoma and paragangliomas
Gild, M. L., Naik, N., Hoang, J., Hsiao, E., McGrath, R. T., Sywak, M. S., Sidhu, S. B., Delbridge, L., Robinson, B. G., Schembri, G. P., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13737 · Cited by 54
Wallace, P. W., Conrad, C., Brückmann, S., Pang, Y. K., Caleiras, E. J., Murakami, M., Korpershoek, E., Zhuang, Z., Rapizzi, E., Kroiß, M., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5472 · Cited by 53
Self-citationMastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression
Alzofon, N., Koc, K. N., Panwell, K., Pozdeyev, N. V., Marshall, C. B., Albuja-Cruz, M. B., Raeburn, C. D., Nathanson, K. L., Cohen, D. L., Wierman, M. E., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0992 · Cited by 53
Ziegler, C. G., Brown, J. W., Schally, A. V., Erler, A., Gebauer, L., Treszl, A., Young, L., Fishman, L. M., Engel, J. B., Willenberg, H. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907843106 · Cited by 51
Self-citationConcomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
Yadav, M. P., Ballal, S., & Bal, C. S. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0484-y · Cited by 51
Ellis, R. J., Patel, D., Prodanov, T., Sadowski, S. M., Nilubol, N., Adams, K. T., Steinberg, S. M., Pacák, K., & Kebebew, E. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.04.027 · Cited by 49
Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes
Janssen, I., Chen, C. C., Zhuang, Z., Millo, C., Wolf, K. I., Ling, A. L., Lin, F. I., Adams, K. T., Herscovitch, P., Feelders, R. A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.187690 · Cited by 48
18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma
Taïeb, D., Jha, A., Guérin, C., Pang, Y. K., Adams, K. T., Chen, C. C., Romanet, P., Roche, P., Essamet, W., Ling, A. L., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02324 · Cited by 48
Lee, H., Jeong, S., Yu, Y., Kang, J., Sun, H., Rhee, J., & Kim, Y. H. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106324 · Cited by 48
Fankhauser, M., Bechmann, N., Lauseker, M., Goncalves, J., Favier, J., Klink, B., William, D., Gieldon, L., Maurer, J., Spöttl, G., et al. (2019) · Endocrinology · doi:10.1210/en.2019-00410 · Cited by 47
Self-citationInhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors In Vitro: Antitumoral Effects
Jin, X., Spöttl, G., Maurer, J., Nölting, S., & Auernhammer, C. J. (2020) · Cancers · doi:10.3390/cancers12020345 · Cited by 47
Self-citationClinical utility of chromogranin A in SDH x‐related paragangliomas
Zuber, S. M., WESLEY, R. A., Prodanov, T., Eisenhofer, G., Pacák, K., & Kantorovich, V. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12245 · Cited by 45
Self-citationNölting, S., García, E., Alusi, G., Giubellino, A., Pacák, K., Korbonits, M., & Grossman, A. B. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0028 · Cited by 45
Self-citationEfficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan
Naruse, M., Satoh, F., Tanabe, A., Okamoto, T., Ichihara, A., Tsuiki, M., Katabami, T., Nomura, M., Tanaka, T., Matsuda, T., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0276 · Cited by 43
Gieldon, L., William, D., Hackmann, K., Jahn, W., Jahn, A., Wagner, J., Rump, A., Bechmann, N., Nölting, S., Knösel, T., et al. (2019) · Cancers · doi:10.3390/cancers11060809 · Cited by 43
Self-citationJawed, I., Velarde, M., Därr, R., Wolf, K. I., Adams, K. T., Venkatesan, A. M., Balasubramaniam, S., Poruchynsky, M. S., Reynolds, J. C., Pacák, K., et al. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0579-4 · Cited by 42
Tufton, N., Shapiro, L., Srirangalingam, U., Richards, P. S., Sahdev, A., Kumar, A., McAndrew, L., Martin, L., Berney, D. M., Monson, J. P., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.13246 · Cited by 39
Daniel, E., Jones, R. N., Bull, M., & Newell-Price, J. D. C. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0595 · Cited by 37
Buitenwerf, E., Berends, A. M. A., van Asselt, A. D. I., Korteweg, T., Greuter, M. J. W., Veeger, N. J. G. M., Links, T. P., Dullaart, R. P. F., & Kerstens, M. N. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.030 · Cited by 37
Kota, S. K., Kota, S. K., Panda, S. K., & Modi, K. D. (2012) · PubMed Central · Cited by 36
Boyd, J. M., Leung, A. A. C., Sadrzadeh, H. S. M., Pamporaki, C., Pacák, K., Deutschbein, T., Fliedner, S. M. J., & Kline, G. A. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0176 · Cited by 36
Tufton, N., Sahdev, A., Drake, W. M., & Akker, S. A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13877 · Cited by 35
Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1
Al‐Sharefi, A., Javaid, U., Perros, P., Ealing, J., Truran, P., Nag, S., Kamaruddin, S., Abouglila, K., Cains, F., Lewis, L. S., et al. (2019) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2019.15.2.95 · Cited by 35
Tena, I., Gupta, G., Tajahuerce, M., Benavent, M., Cifrián, M., Falcón, A., Fonfría, M., Olmo-García, M. I. D., Reboll, R., Conde-Moreno, A. J., et al. (2018) · Clinical Medicine Insights Oncology · doi:10.1177/1179554918763367 · Cited by 34
Closing the GAPP on predicting metastases
Eisenhofer, G., & Tischler, A. S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.41 · Cited by 31
Self-citationHigh-Throughput Screening for Growth Inhibitors Using a Yeast Model of Familial Paraganglioma
Bancos, I., Bida, J. P., Tian, D., Bundrick, M., John, K., Holte, M. N., Her, Y. F., Evans, D. L., Saenz, D. T., Poeschla, E. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056827 · Cited by 27
Activating FGFR1 Mutations in Sporadic Pheochromocytomas
Welander, J., Łysiak, M., Brauckhoff, M., Brunaud, L., Söderkvist, P., & Gimm, O. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4320-0 · Cited by 26
Deutschbein, T., Faßnacht, M., Weismann, D., Reincke, M., Mann, K., & Petersenn, S. (2014) · Clinical Endocrinology · doi:10.1111/cen.12590 · Cited by 24
Wakabayashi, H., Inaki, A., Yoshimura, K., Murayama, T., Imai, Y., Higuchi, T., Jinguji, M., Shiga, T., & Kinuya, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43880-6 · Cited by 22
Pang, Y. K., Gupta, G., Yang, C., Wang, H., Huynh, T., Abdullaev, Z., Pack, S., Percy, M. J., Lappin, T. R. J., Zhuang, Z., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4127-x · Cited by 21
Nambuba, J., Därr, R., Janssen, I., Bullova, P., Adams, K. T., Millo, C., Bourdeau, I., Kassai, A., Yang, C., Kebebew, E., et al. (2015) · AACE Clinical Case Reports · doi:10.4158/ep15759.cr · Cited by 14
Complete Remission in Metastatic Pheochromocytoma Treated with Extensive Surgery
Arnas-Leon, C., Sánchez, V., Santana-Suarez, A. D., Quintana-Arroyo, S., Acosta, C. I. S., & Martín, F. J. M. (2016) · Cureus · doi:10.7759/cureus.447 · Cited by 14
Screening guidelines and recommendations for patients at high risk of developing endocrine cancers
Geurts, J. L., Strong, E. A., Wang, T. S., Evans, D. B., & Clarke, C. N. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25869 · Cited by 14
Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion
Li, M., Pamporaki, C., Fliedner, S. M. J., Timmers, H. J. L. M., Nölting, S., Beuschlein, F., Prejbisz, A., Remde, H., Robledo, M., Bornstein, S. R., et al. (2021) · Discover Oncology · doi:10.1007/s12672-021-00404-x · Cited by 14
Self-citationAn analysis of surveillance screening for SDHB-related disease in childhood and adolescence
Tufton, N., Shapiro, L., Sahdev, A., Kumar, A., Martin, L., Drake, W. M., Akker, S. A., & Storr, H. L. (2019) · Endocrine Connections · doi:10.1530/ec-18-0522 · Cited by 12
Cited by
Wang, Y., Liu, B., Li, F., Zhang, Y., Gao, X., Wang, Y., & Zhou, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274239 · Cited by 18
Metadata
- Authors
- Nölting, S., Bechmann, N., Taieb, D., Beuschlein, F., Fassnacht, M., Kroiss, M., Eisenhofer, G., Grossman, A., & Pacak, K.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-06-19
- Volume
- 43
- Issue
- 2
- Pages
- 199-239
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W3166036810
- Cited by
- 417
- References
- 196
- FWCI
- 52.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.